Emmaus Life Sciences, Inc. (EMMA) Stock Price & Analysis
Emmaus Life Sciences, Inc. (EMMA) fell 6.36% to USD 0.01 as of June 13, 2026 at 11:46 UTC, according to Nexqual real-time market data.
EMMA last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 4 shares. Market capitalization is $722,939, with a 52-week range of USD 0.01–0.02 (OQB). Source: Nexqual, June 13, 2026 at 11:46 UTC.
Key Statistics (as of June 13, 2026 at 11:46 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▼ 6.36% (down) |
| Previous Close | USD 0.01 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.02 |
| Volume | 4 shares |
| Market Cap | $722,939 |
| Exchange | OQB |
Technical Analysis (EMMA)
Nexqual's technical model rates EMMA "SELL" based on 1 bullish and 4 bearish signals across 124 daily candles, as of June 13, 2026 at 11:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 51.65 (neutral) |
| vs SMA50 | Above (USD 0.01) |
| MACD | 0 (negative) |
Analyst Ratings (EMMA)
Wall Street analysts rate EMMA "None", per Nexqual as of June 13, 2026 at 11:46 UTC.
| Consensus Rating | None |
|---|
Earnings (EMMA)
Source: Nexqual, June 13, 2026 at 11:46 UTC.
Financials & Fundamentals (EMMA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, June 13, 2026 at 11:46 UTC.
Financial Health Score (EMMA)
Nexqual rates Emmaus Life Sciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 13, 2026 at 11:46 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (EMMA)
| Insider Ownership | +47.08% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 70.19M |
| Short % of Float | +0.09% |
Source: Nexqual, June 13, 2026 at 11:46 UTC.
Leadership (EMMA)
Emmaus Life Sciences, Inc. is led by Willis C. Lee M.S. (age 65), CEO & Chairman of the Board, per Nexqual as of June 13, 2026 at 11:46 UTC.
| CEO & Chairman of the Board | Willis C. Lee M.S. (age 65) |
|---|
From Emmaus Life Sciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
- The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older.
- It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELOX | Eloxx Pharmaceuticals, Inc. Common Stock | USD 13.52 | ▲ 22.91% |
| MRZM | Marizyme, Inc. | USD 0 | ▲ 0% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| SYBX | Synlogic, Inc. | USD 0.74 | ▼ 6.33% |
| ARMP | Armata Pharmaceuticals, Inc. | USD 7.58 | ▲ 0.26% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 13, 2026 at 11:46 UTC. This page is informational and not investment advice.